Diversified revenue and earnings base with four strong business segments
Leading positions in non-cyclical markets with predictable growth
Industry-leading organic growth in all business segments
Strong earnings performance and cash flow generation
Attractive shareholder returns
Prudent financial management
Dilaudid (HYDROmorphone HCl injection) is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the third product launch for the Simplist™ line following ownership by Fresenius Kabi.
Fresenius successfully placed €1.0 billion of Schuldschein Loans. Given the substantial investor demand, the volume of the issuance was significantly upsized. The Schuldschein Loans were issued in tranches of five, seven and ten years with fixed and variable interest rates. The proceeds will be used general corporate purposes and the acquisition of Quirónsalud. Funding of the transaction will be on January 31, 2017. More than 230 investors participated. The placement was arranged by Bayerische Landesbank, Deutsche Bank AG, DZ BANK and NORD/LB Norddeutsche Landesbank Girozentrale.
Heparin Sodium, an anticoagulent, is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the second new product launch for the Simplist™ line following ownership by Fresenius Kabi. The launch expands Fresenius Kabi’s overall Heparin portfolio.
CATSmart is Fresenius Kabi’s next-generation continuous autotransfusion system, which helps reduce blood loss during surgery. CATSmart will be distributed in the U.S. by Terumo Cardiovascular Group. Fresenius Kabi USA and Terumo Cardiovascular Group have signed an exclusive, five-year distribution agreement for CATSmart.
Tigecycline, an antibiotic, expands Fresenius Kabi's anti-infective portfolio.
Fresenius Helios has laid the foundation stone for a new main building at HELIOS Hospital Dr. Horst Schmidt Kliniken in the German city of Wiesbaden, near Frankfurt. The seven-story structure, with 96,000 square meters (about 1 million square feet) of floor space, is being erected beside the existing clinic. It will have 22 operating rooms, more than 900 beds, and a design that significantly reduces distances and waiting times for patients. HELIOS is investing about €200 million in the new building, while the state of Hesse is contributing €68 million. Completion is scheduled for 2020.
Bivalirudin for Injection, a direct thrombin inhibitor, expands the company's anticoagulant portfolio.
Fresenius increased its 2013 Senior Credit Agreement by €1.2 billion incremental facilities as a further step to fund the acquisition of IDC Salud Holding S.L.U. (Quironsalud) by Fresenius Helios. A bridge facility of €3.75 billion was already signed in September 2016. The incremental facilities consist of an incremental term loan A of €900 million and an incremental revolving facility of €300 million. The transaction was well received by investors and substantially oversubscribed. More than 40 financial institutions participated.
A website published by Fresenius Kabi Germany on nutritional therapies for different types of patients has won the Health Media Award. The jury praised www.ernaehrungstherapie-hilft.de for its comprehensive information, a user-friendly presentation, and the site's attractive interactive elements. The German-language site targets not only patients and their family members, but also physicians, nutritionists and caregivers.
Two of Fresenius Vamed’s rehabilitation clinics in Austria have again been certified as “World Hospitals” by the Joint Commission International (JCI). The renewed certifications mean the Rehabilitation Clinic Montafon and the Neurological Therapy Center Gmundnerberg remain among the approximately 800 hospitals worldwide recognized by the JCI as top-tier facilities. A certification as a World Hospital is valid for three years. Quality standards are verified annually by the U.S.-based JCI, the world’s leading competence center for quality and patient safety in healthcare.
Ketorolac Tromethamine, a nonsteroidal anti-inflammatory drug, is now available in the company’s Simplist™ ready-to-administer prefilled syringe in the United States. This marks the first new product launch for the Simplist™ line following ownership by Fresenius Kabi.
Daptomycin, an antibiotic, expands Fresenius Kabi's anti-infective Portfolio.
Fresenius Vamed has successfully completed another major project in Germany’s healthcare system, an emergency care center at the Charité university hospital in Berlin. The new center was built in partnership with the construction company Züblin for about €70 million. It will cover about 8,000 square meters (86,000 square feet) and host 15 operating rooms, a 71-bed intensive care ward and a central emergency department.
The price increase for hospital services in Germany has been set at 2.50% for 2017. This is in line with the level of past years.
Construction has begun at the HELIOS hospital in Hildesheim, a city in the German state of Lower Saxony, on a fourth hospital block. The nearly 6,000-square-meter (65,000 square feet), three-story building will house wards for ear, nose and throat medicine, oral-facial, and thoracic surgery. A pulmonary clinic acquired in 2014, currently situated in nearby Diekholzen, will be relocated to the new building including a sleep lab twice as large as the existing one. HELIOS is investing about €13 million in the new block of wards. Completion is expected in 2018.
Following Fresenius’ announcement to acquire the largest Spanish hospital operator Quirónsalud, the rating agencies Standard & Poor’s (BBB-, stable), Moody’s (Baa3, stable) and Fitch (BBB-, stable) are affirming the corporate credit ratings of Fresenius.
A consortium led by Vamed has handed over the first new building at the University Hospital in Kiel. The new unit took less than four months to build and will house a haematology-oncology ward. The building is part of a comprehensive construction and modernization project at the hospital. Completion is scheduled for 2019.
Fresenius Kabi is expanding its Melrose Park, Illinois site to significantly increase capacity for the production of injectable generic pharmaceuticals. The multi-stage expansion at the facility, just outside of Chicago, will include construction of a number of new buildings. Completion is scheduled for 2026, following an investment of nearly $250 million. www.fresenius-kabi.us
The “Wir für Gesundheit” hospital network in Germany continues to grow: PlusCard, a supplementary company health insurance, will be accepted starting immediately at Klinikum Ingolstadt. With more than 1,000 beds, this hospital is one of the largest in the state of Bavaria. PlusCard offers employers various coverage options to provide employees with different levels of service and comfort. “Wir für Gesundheit” was formed by hospital operators Asklepios, Fresenius Helios and Rhön, and has more than 120 partner hospitals in Germany committed to comply with quality standards far higher than those required by law.
Fitch has upgraded the corporate credit rating of Fresenius from BB+ to BBB- with a stable outlook. The upgrade reflects Fitch's view that Fresenius' business profile has improved over the last years driven by increasing scale and diversification as well as strong profitability and cash generation. In addition, Fitch considers the underlying operations to be mature and defensive with low cyclicality and low volatility of earnings. Standard & Poor’s and Moody’s have upgraded the corporate credit rating of Fresenius to investment grade in 2015.
Quarterly Financial Report Q3 2016 (IFRS) (PDF, 373 KB)
Quarterly Financial Report Q3 2016 (US-GAAP) (PDF, 337 KB)
Quarterly Financial Report Q2 2016 (IFRS) (PDF, 333 KB)
Quarterly Financial Report Q2 2016 (US-GAAP) (PDF, 369 KB)
Fresenius Factsheet Q3 2016 (PDF, 311 KB)
Quarterly Financial Report Q1 2016 (IFRS) (PDF, 309 KB)
Quarterly Financial Report Q1 2016 (US-GAAP) (PDF, 830 KB)
Annual Report 2015 (US-GAAP) (PDF, 3.18 MB)
Quarterly Financial Report Q3 2015 (US-GAAP) (PDF, 327 KB)
Investor Relations General Presentation (PDF, 495 KB)
Quarterly Financial Report Q2 2015 (US-GAAP) (PDF, 375 KB)
Quarterly Financial Report Q1 2015 (US-GAAP) (PDF, 317 KB)
Annual Report 2014 (US-GAAP) (PDF, 3.04 MB)
Quarterly Financial Report Q3 2014 (US-GAAP) (PDF, 400 KB)
Quarterly Financial Report Q2 2014 (US-GAAP) (PDF, 386 KB)
Quarterly Financial Report Q1 2014 (US-GAAP) (PDF, 337 KB)
Annual Report 2013 (US-GAAP) (PDF, 3.27 MB)
Quarterly Financial Report Q3 2013 (US-GAAP) (PDF, 368 KB)
Quarterly Financial Report Q2 2013 (US-GAAP) (PDF, 403 KB)
Quarterly Financial Report Q1 2013 (US-GAAP) (PDF, 293 KB)